China's pharmaceutical market will continue to develop at a high rate:
1, transformation and innovation. This must be the best path, innovation must be the future trend, but because the innovative drug itself is 5-8 years of R & D cycle, the need to layout the R & D team, spending a relatively large R & D investment, not this year want to layout the next year can be done, so the transition of innovation, although it is one of the best track, but it takes time.
2, if innovation is difficult for him, may wish to consider the second path, the development of difficult to imitate drugs, such as respiratory agents, product patents have expired, but because of its own dosage form of the difficulties, may still have some production barriers, this may be the second path, assuming that the innovation does not work, you can consider the development of difficult to imitate varieties, the more typical of the health of the yuan, such as the company are doing very well.
3, if the second is also difficult, the third path is to extend the product line, listing a generic short-term will be faced with collection, one can not produce 10, 20, and finally there are always products can enter the collection, bring incremental, as long as each year to ensure that the echelon of the product listing, the future can also realize the cash flow, to achieve profitability, which is also a path, the current part of the company also to this layout.
4, for generic drug companies we summarize the existing pipeline we consider more about the future impact of the collection, what is the future steady state situation, we will consider more about the future of the new pipeline, the future direction of development, this is the direction we need to pay attention to, is the chemical generics are probably the characteristics of the study and the way.
5, traditional Chinese medicine prescription drugs is also the current market attention is relatively not so high segment, we believe that the core reason lies in the traditional Chinese medicine companies most of the products in the research and development of relatively few, may be more to analyze the existing product line of the ladder, this piece of the direction with the current attention to innovation there is some detachment, so that led to the traditional Chinese medicine is not so much attention in the current period.
On the one hand, we need to pay attention to its existing products, what is the big category, the big category of the field is not a big field, the price of the product will be under pressure, and then look at the competition pattern how, is not going to enter the medical insurance, this is what we need to pay attention to the point.